Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)

The purpose of this study is to elucidate whether the individualized medicine based on NAT2 gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug therapy for the pulmonary tuberculosis with isoniazid.

Inclusion Criteria:

• Newly diagnosed pulmonary tuberculosis patients
• Informed consent including pharmacogenomic analysis

Exclusion Criteria:

• Abnormal liver and kidney function test before treatment
• Long-term use of steroids and/or immunodepressants
• Inadequate clinical conditions